S5-05.3 – Strategies to Improve NIT reliability in Diagnosing and Staging MASH Fibrosis
This conversation looks at different strategies to improve NITs in the diagnosis and staging of patients with advanced MASH Fibrosis.
March 10, 2024
This conversation looks at different strategies to improve NITs in the diagnosis and staging of patients with advanced MASH Fibrosis.
This conversation focuses on why it will be challenging to use currently-available NITs to stage patients with advanced MASH fibrosis (F2/F3) accurately with current test options.
This conversation focuses on why use of NITs is such a pivotal issue for MASH treatment and drug adoption, particularly if, as expected, the first MASH drug is approved this month.
In the podcast episode, panelists delve into the shifting landscape of diagnosing and treating F2/3 MASH patients using non-invasive tests (NITs). They discuss challenges with current diagnostic tools, upcoming blood-based tests, and the potential impact of new drugs like resmetirom and GLP-1s on treatment strategies, aiming to optimize changes in the industry once a drug is approved.
Zobair Younossi discusses the disease burden of MASLD as characterized in his recent publication “Understanding the Burden of Fatty Liver Disease: Time for Action”
Global NASH Council Chair Zobair Younossi joins the Surfers to discuss his recent review article on MASLD epidemiology and what stakeholders can do to help stem the tsunami of new patients.
Patient advocates Neeraj Mistry of the Fatty Liver Foundation and Jenn Leigh Jones of the Society for Sober Liver Survival join Louise Campbell and Roger Green to discuss the merging of their organizations and the impact of the new nomenclature on how patients might look at their disease.
Hepatology researcher and Key Opinion Leader Naim Alkhouri joins Louise Campbell and Roger Green to discuss advances in drug development and NITs and to share thoughts about efficacious use of clinical care pathways.
This conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers what the panelists found exciting, important or striking about the presentations of clinical trial results at TLM 2023.
Profs. Laurent Castera and Scott Friedman join Louise Campbell and Roger Green to discuss highlights of the recent TLM2023 conference.